Silo Pharma, Inc. (SILO) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Los analistas estiman Beneficio por acción (EPS) de $-0.56 y ingresos de $0.00B para el próximo año fiscal.
Historial de Beneficio por acción (EPS): 2024: real $-1.19 vs est $-0.56 (no alcanzó -112.5%). 2025: real $-0.50 vs est $-0.70 (superó +28.6%). Precisión del analista: 54%.
Estimaciones de BPA — SILO
54%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.19
vs Est –$0.56
▼ 52.9% off
2025
Actual –$0.50
vs Est –$0.70
▲ 40.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Estimaciones de Ingresos — SILO
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.000B
vs Est $0.000B
▲ 0.1% off
2025
Actual $0.000B
vs Est $0.000B
▲ 0.1% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
